Literature DB >> 19372438

What kind of randomized trials do we need?

Merrick Zwarenstein1, Shaun Treweek.   

Abstract

Mesh：

Year:  2009        PMID： 19372438      PMCID： PMC2679816          DOI： 10.1503/cmaj.082007

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  11 in total

Review 1.  [A critical review of the pragmatic clinical trial].

Authors:  Carles Vallvé
Journal:  Med Clin (Barc)       Date:  2003-09-27       Impact factor: 1.725

2.  Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy.

Authors:  Sean R Tunis; Daniel B Stryer; Carolyn M Clancy
Journal:  JAMA       Date:  2003-09-24       Impact factor: 56.272

3.  Why we will remain pragmatists: four problems with the impractical mechanistic framework and a better solution.

Authors:  Andrew D Oxman; Carl Lombard; Shaun Treweek; Joel J Gagnier; Malcolm Maclure; Merrick Zwarenstein
Journal:  J Clin Epidemiol       Date:  2009-05       Impact factor: 6.437

4.  A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers.

Authors:  Kevin E Thorpe; Merrick Zwarenstein; Andrew D Oxman; Shaun Treweek; Curt D Furberg; Douglas G Altman; Sean Tunis; Eduardo Bergel; Ian Harvey; David J Magid; Kalipso Chalkidou
Journal:  J Clin Epidemiol       Date:  2009-05       Impact factor: 6.437

5.  A pragmatic resolution.

Authors:  Andrew D Oxman; Carl Lombard; Shaun Treweek; Joel J Gagnier; Malcolm Maclure; Merrick Zwarenstein
Journal:  J Clin Epidemiol       Date:  2009-05       Impact factor: 6.437

6.  Explaining pragmatic trials to pragmatic policymakers.

Authors:  Malcolm Maclure
Journal:  J Clin Epidemiol       Date:  2009-05       Impact factor: 6.437

7.  STREPTOMYCIN treatment of pulmonary tuberculosis.

Authors: 
Journal:  Br Med J       Date:  1948-10-30

8.  Explanatory and pragmatic attitudes in therapeutical trials.

Authors:  D Schwartz; J Lellouch
Journal:  J Chronic Dis       Date:  1967-08

9.  A new 'mechanistic-practical" framework for designing and interpreting randomized trials.

Authors:  Paul J Karanicolas; Victor M Montori; P J Devereaux; Holger Schünemann; Gordon H Guyatt
Journal:  J Clin Epidemiol       Date:  2008-05-12       Impact factor: 6.437

10.  Improving the reporting of pragmatic trials: an extension of the CONSORT statement.

Authors:  Merrick Zwarenstein; Shaun Treweek; Joel J Gagnier; Douglas G Altman; Sean Tunis; Brian Haynes; Andrew D Oxman; David Moher
Journal:  BMJ       Date:  2008-11-11
View more
  23 in total

1.  What have we learned about trial design from NIMH-funded pragmatic trials?

Authors:  John March; Helena C Kraemer; Madhukar Trivedi; John Csernansky; John Davis; Terence A Ketter; Ira D Glick
Journal:  Neuropsychopharmacology       Date:  2010-08-25       Impact factor: 7.853

2.  Moving from efficacy to effectiveness trials in prevention research.

Authors:  Erica Marchand; Eric Stice; Paul Rohde; Carolyn Black Becker
Journal:  Behav Res Ther       Date:  2010-11-02

3.  Cross-disciplinary research in cancer: an opportunity to narrow the knowledge-practice gap.

Authors:  R Urquhart; E Grunfeld; L Jackson; J Sargeant; G A Porter
Journal:  Curr Oncol       Date:  2013-12       Impact factor: 3.677

4.  The impact of provider-initiated (opt-out) HIV testing and counseling of patients with sexually transmitted infection in Cape Town, South Africa: a controlled trial.

Authors:  Natalie Leon; Pren Naidoo; Catherine Mathews; Simon Lewin; Carl Lombard
Journal:  Implement Sci       Date:  2010-01-30       Impact factor: 7.327

5.  Research-grade data in the real world: challenges and opportunities in data quality from a pragmatic trial in community-based practices.

Authors:  Anna A Divney; Priscilla M Lopez; Terry T Huang; Lorna E Thorpe; Chau Trinh-Shevrin; Nadia S Islam
Journal:  J Am Med Inform Assoc       Date:  2019-08-01       Impact factor: 4.497

6.  Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa.

Authors:  M Loveday; K Wallengren; A Voce; B Margot; T Reddy; I Master; J Brust; K Chaiyachati; N Padayatchi
Journal:  Int J Tuberc Lung Dis       Date:  2012-02       Impact factor: 2.373

7.  Comparative efficacy of LEAP, TEACCH and non-model-specific special education programs for preschoolers with autism spectrum disorders.

Authors:  Brian A Boyd; Kara Hume; Matthew T McBee; Michael Alessandri; Anibal Gutierrez; Leanne Johnson; Laurie Sperry; Samuel L Odom
Journal:  J Autism Dev Disord       Date:  2014-02

Review 8.  A review of pragmatic trials found a high degree of diversity in design and scope, deficiencies in reporting and trial registry data, and poor indexing.

Authors:  Stuart G Nicholls; Kelly Carroll; Spencer Phillips Hey; Merrick Zwarenstein; Jennifer Zhe Zhang; Hayden P Nix; Jamie C Brehaut; Joanne E McKenzie; Steve McDonald; Charles Weijer; Dean A Fergusson; Monica Taljaard
Journal:  J Clin Epidemiol       Date:  2021-03-28       Impact factor: 6.437

9.  Designing a valid randomized pragmatic primary care implementation trial: the my own health report (MOHR) project.

Authors:  Alex H Krist; Beth A Glenn; Russell E Glasgow; Bijal A Balasubramanian; David A Chambers; Maria E Fernandez; Suzanne Heurtin-Roberts; Rodger Kessler; Marcia G Ory; Siobhan M Phillips; Debra P Ritzwoller; Dylan H Roby; Hector P Rodriguez; Roy T Sabo; Sherri N Sheinfeld Gorin; Kurt C Stange
Journal:  Implement Sci       Date:  2013-06-25       Impact factor: 7.327

10.  Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Authors:  Nasim Nehzat; Omid Mirmosayyeb; Mahdi Barzegar; Reza Vosoughi; Erfane Fazeli; Vahid Shaygannejad
Journal:  Neurol Res Int       Date:  2021-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.